Skip to main content
Clinical Trials/NCT04910217
NCT04910217
Recruiting
Not Applicable

Robot-Assisted Gait Therapy in the Subacute Phase of First Ischemic Stroke

University Hospital Ostrava1 site in 1 country80 target enrollmentMay 1, 2022
ConditionsIschemic Stroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemic Stroke
Sponsor
University Hospital Ostrava
Enrollment
80
Locations
1
Primary Endpoint
Functional Ambulation Category (FAC) at 3 months
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Robot-assisted gait training (RAGT) represents a modern concept of neurorehabilitation in stroke patients. This single-center randomized parallel-group neurorehabilitation trial with blinded primary outcome assessment is aimed at patients after the first-ever ischaemic stroke in the anterior or posterior cerebral circulation.

Detailed Description

The main aim is to determine, whether the RAGT by using the Lokomat exoskeleton device (Hoccoma, Switzerland) plus the protocol-defined conventional rehabilitation versus conventional rehabilitation improves the gait of post-stroke patients after 6 months. Both groups are treated with the protocol-defined rehabilitation (ergotherapy and physiotherapy) for 60 min 5 times a week, a total of 15 times within 3 weeks (a total of 1200 min). The Lokowalkers group undergoes the RAGT using the Lokomat Pro Freed device for 20-50 minutes 5 times a week for a total of 15 times for 3 weeks (a total of 1800 minutes). The primary endpoint is the Functional Ambulation Category (FAC) after 3 months. Secondary endpoints include FAC (after 15th therapy), 10-meter walk test (10MWT) (after 15th therapy, after 3 months), Timed Up and Go Test (TUG) (after 15th therapy and after 3 months, 3-months modified Rankin Scale (mRS), and Berg Balance Scale (BBS, after 15th therapy, after 3 months).

Registry
clinicaltrials.gov
Start Date
May 1, 2022
End Date
December 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital Ostrava
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • signed informed consent by the participant or legal representative
  • interval between stroke and first rehabilitation session \< 6 weeks (study target within 2 weeks)
  • age \> 18 years
  • early modified Rankin scale (mRS) 2 to 4 (pre-stroke mRS 0 to 1)
  • early FAC of 0 to 3 (pre-stroke FAC of 5)
  • standing ability with support up to 3 minutes and vertical tolerance \> 15 minutes

Exclusion Criteria

  • inability or refusal to sign an informed consent
  • history of stroke or another brain disease (tumour, multiple sclerosis, brain or spinal cord injury)
  • severe internal, oncological, or surgical comorbidity preventing long-term re-habilitation or causing chronic or progressive gait disorder
  • limited collaboration of any reason, moderate or severe dementia assessed by using the Montreal Cognitive Assessment (MoCA) scale
  • impaired skin integrity in the lower torso and limbs preventing the use of Lokomat device
  • limitations given by the Lokomat exoskeleton device (weight \> 135 kg, thigh-length 23-35 cm, shank length 35-47cm)
  • limitations given by the leg/lower body exerciser (weight \> 180 kg, height \< 120 cm or \> 200 cm, (sub)acute lower limb fractures, deep vein thrombosis, skin disintegration)
  • any contraindication to perform brain MRI

Outcomes

Primary Outcomes

Functional Ambulation Category (FAC) at 3 months

Time Frame: 3 months

Functional Ambulation Category (FAC) - the scale range is from 0 to 5. The value at 6-months will be observed.

Secondary Outcomes

  • Functional Ambulation Category (FAC) (after 3 weeks)(3 weeks)
  • 10-meter walk test (10-MWT) (after 3 weeks and 3 months)(up to 3 months)
  • Timed Up and Go Test (TUG) (after 3 weeks, after 3 months)(up to 3 months)
  • 3-months modified Rankin Scale (mRS)(up to 3 months)
  • Adverse effects(up to 3 years)
  • Early termination of the study(up to 3 years)
  • Reason/s for the termination(up to 3 years)
  • Berg Balance Scale (BBS, after 3 weeks, after 3 months)(up to 3 months)
  • Study-related death or death unrelated to study(up to 3 years)

Study Sites (1)

Loading locations...

Similar Trials